Commerce Bank Acquires 148 Shares of Repligen Co. (NASDAQ:RGEN)

Posted by on Aug 11th, 2023

Commerce Bank boosted its holdings in Repligen Co. (NASDAQ:RGEN – Free Report) by 11.3% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,454 shares of the biotechnology company’s stock after acquiring an additional 148 shares during the quarter. Commerce Bank’s holdings in Repligen were worth $245,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Fortis Capital Advisors LLC purchased a new stake in Repligen in the 4th quarter valued at about $35,000. Whittier Trust Co. increased its stake in Repligen by 108.6% in the 1st quarter. Whittier Trust Co. now owns 242 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 126 shares during the last quarter. Achmea Investment Management B.V. purchased a new stake in Repligen in the 4th quarter valued at about $49,000. Covestor Ltd increased its stake in Repligen by 58.7% in the 1st quarter. Covestor Ltd now owns 484 shares of the biotechnology company’s stock valued at $91,000 after buying an additional 179 shares during the last quarter. Finally, State of Wyoming increased its stake in Repligen by 21.6% in the 4th quarter. State of Wyoming now owns 710 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 126 shares during the last quarter. Institutional investors own 96.28% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $172.45 on Friday. The firm has a fifty day moving average price of $158.67 and a two-hundred day moving average price of $167.32. Repligen Co. has a one year low of $134.64 and a one year high of $262.26. The company has a market cap of $9.62 billion, a price-to-earnings ratio of 71.26, a PEG ratio of 3.88 and a beta of 1.01.

Repligen (NASDAQ:RGEN – Get Free Report) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.04. Repligen had a net margin of 18.92% and a return on equity of 7.83%. The company had revenue of $159.20 million during the quarter, compared to the consensus estimate of $165.93 million. During the same period in the previous year, the firm posted $0.91 EPS. The firm’s revenue was down 23.3% compared to the same quarter last year. Equities research analysts expect that Repligen Co. will post 1.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Benchmark decreased their price objective on shares of Repligen from $230.00 to $210.00 in a research note on Wednesday, May 3rd. Stifel Nicolaus decreased their price target on shares of Repligen from $210.00 to $200.00 in a research note on Wednesday, June 28th. Royal Bank of Canada raised their price target on shares of Repligen from $157.00 to $195.00 and gave the stock an “outperform” rating in a research note on Thursday, August 3rd. Wells Fargo & Company initiated coverage on shares of Repligen in a research note on Thursday, July 20th. They set an “overweight” rating and a $185.00 price target for the company. Finally, TheStreet lowered shares of Repligen from a “b-” rating to a “c+” rating in a research note on Monday, May 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $199.44.

Get Our Latest Analysis on Repligen

About Repligen

(Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Featured Stories

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.